Hochdosis-Chemotherapie mit anschließender autologer Stammzelltransplantation
In the years 1992 to 1998 a number of 59 patients in the department of haematology-oncology of the university-hospital of the RWTH-Aachen have been treated with high-dose chemotherapy with following autologous stem cell transplantation (PBSCT). The high-dose chemotherapy with autologous stem cell transplantation is a treatment superior to the conventional chemotherapy in a set of tumor diseases. The side-effects of a chemotherapy on the hematopoeisis can be overcome by the autologous stem cell transplantation, which otherwise often represent the limiting factor. A complete remission can be achieved by the possible increase of the dose intensity, at the same time can the duration of the remission be extended and also higher healing rates with certain tumor diseases be achieved at a larger number of patients. The PBSCT is surely feasible in centers with appropriate experience and machine as well as personnel equipment. As a possibility of treatment the PBSCT is accepted by most patients and also in the review in the very most cases positively judged. A female patient developed CMV-pneumonia in the consequence of the high-dose therapy and deceased at day 50 after transplantation according to a multi-organ failure. At two patients no sufficient reconstitution of haematopoiesis took place after the transplantation, so that a second stem-cell return took place, which led to a full haematological reconstitution. On 30.06.2001 still 23 patients were alive and in regular follow-up, 10 of them free of relapse since the transplantation. In the deceased patients the occurrence of a relapse of the malignant disease was the main cause of death.
info:eu-repo/classification/ddc/610, Medizin
Networked Digital Library of Theses and Dissertations
Publikationsserver der RWTH Aachen University